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Arrest in the embryologic intestinal rotation around the superior mesenteric artery prevents proper
mesenteric attachment and subjects the gut to volvulus and ischemia which may lead to bowel
resection. The length of non-viable resected bowel has been shown by Teitelbaum et al. to be an
independent predictor of survival in patients with postoperative short bowel syndrome (RR ¼ 5.74,
P ¼ .003). Non-occlusive mesenteric ischemia (NOMI) is a feed-forward loop of vasoconstriction that
aggravates the primary ischemic injury. It is an initially reversible process and a potential point of
intervention for preservation of viable bowel. The Boley et al. algorithm for management of adult
NOMI utilizes intravascular papaverine infusion to increase intracellular cAMP, decreasing calcium
concentration and halting vasospasm. We present a modiﬁed version of this approach using topical
papaverine in the setting of neonatal post-ischemic NOMI, with the goal of minimizing bowel
resection.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Arrest in the embryologic intestinal rotation around the superior
mesenteric artery prevents proper mesenteric attachment and sub-
jects the gut to possible volvulus and ischemia. Delayed surgical
correction of this condition may be complicated by short bowel syn-
drome (SBS). Thepreservationof intestinal length signiﬁcantly reduces
mortality in infants in whom SBS develops as a complication [1].
Non-occlusive mesenteric ischemia (NOMI) is a feed-forward
loop of vasoconstriction that aggravates the primary ischemic
injury. It is an initially reversible process and a potential point of
intervention for preservation of viable bowel.
The Boley et al. algorithm for management of adult NOMI uti-
lizes intravascular papaverine infusion to increase intracellular
cAMP, decreasing calcium concentration and halting vasospasm.
We present a modiﬁed version of this approach using topical
papaverine in the setting of neonatal post-ischemic NOMI, with the
goal of minimizing bowel resection [2].
Here we utilized topical papaverine, a phosphodiesterase
inhibitor commonly used in treating adult NOMI, in a newborn.Inc. This is an open access article u1. Case report
The baby boy was delivered at 40 þ 3 weeks gestation via
normal spontaneous vaginal delivery to a 34-year-old gravida 1
para 1 mother with standard prenatal care throughout an un-
complicated pregnancy. Despite the premature rupture of
membranes 24 h prior to delivery, the Apgar score was 9/9, and
no resuscitation was required. Birth weight was 3810 g and
length was 35.5 cm.
The baby was seen in the clinic at 11 days of life with one-day
history of dark yellow/green projectile vomiting after feeding.
Physical examination showed a distended and tympanitic
abdomen. The baby was admitted emergently. An upper GI series
was performed expeditious to rule out other causes of intestinal
obstruction after initial resuscitation, which showed ﬁndings
consistent with malrotation and midgut volvulus. The baby was
then promptly brought to the OR. An exploratory laparotomy with
Ladd procedure and detorsion of malrotation was performed
without complication. The postoperative course was uneventful
and the baby was discharged on the fourth postoperative day
(POD).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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history of nonbilious vomiting after feeding and non-bloody diar-
rhea without signiﬁcant abdominal distention. The baby was
admitted to the pediatric intensive care unit (PICU) and laboratory
studies showed elevated lactate and metabolic acidosis requiring
electrolyte management as well as supportive treatment for
possible partial bowel obstruction. The baby’s condition improved
signiﬁcantly after initial resuscitation with IV ﬂuids and NG
drainage. However, on POD 16, the baby subsequently developed
bilious vomiting with increased abdominal distention and tender-
ness. Abdominal X-ray showed pneumatosis coli and portal venous
gas. The baby was started on IV antibiotics and aggressive resus-
citation in preparation for an emergent exploratory laparotomy.
At exploration, there was a large amount of dark, foul-smelling
peritoneal ﬂuid and the bowel loops appeared dusky and ischemic
with multiple areas of bowel to bowel adhesions and segmental
volvulus which was untwisted. Ischemia of majority of the small
bowel was noted except for a viable 49 cm proximal to the cecum
and 13 cm of the proximal jejunum. Adhesiolysis and small bowel
decompression through a small enterotomy were done. The
enterotomy was then subsequently closed. The decision was made
not to perform bowel resection with a planned second look oper-
ation within the next 24 h for possible bowel recovery. Four milli-
liters of 30mg/2mL papaverinewere introduced into the peritoneal
cavity over the intestines. The abdomen was closed and gently
massaged to further distribute the papaverine. The patient was
brought back to the PICU intubated for further care.
A second look laparotomy was done 24 h later with the ﬁndings
of marked bowel improvement. Thirty-seven centimeters of prox-
imal small bowel, including duodenum and jejunum, and ﬁfty-ﬁve
centimeters of distal small bowel, including the ileocecal valve,
were viable and left behind after jejunal resection with a proximal
jejunostomy and a distal ileostomy.
The postoperative course was uneventful. However, 24 days
later, the baby developed intestinal obstruction in proximal jeju-
nostomy secondary to adhesions requiring adhesiolysis. The patient
recovered well from the operation and then came back another 24
days later for a resection and closure of the enterostomies. The baby
has been thriving well with normal growth and development. Baby
did not require home total parenteral nutrition throughout the
course of treatment.
2. Discussion
Intestinal rotational anomalies are not uncommon in neonatal
patients, occurring in about 1 in 200 to 1 in 500 live births [3]. Out
of these anomalies, symptomatic malrotation is estimated to occur
in 1 in 6000 live births [4]. About 50e65% of these symptomatic
cases will present by one month; however, more recent national
retrospective data analysis suggest that the number may be much
lower [5]. The pathophysiology of intestinal malrotation has been
extensively studied.
The current standard of treatment for malrotation is the Ladd
procedure. The procedure widens the base of the mesentery to
minimize the risk of future volvulus. The preservation of intestinal
length when bowel resection is necessary for removal of non-viable
bowel in the case of volvulus is of critical importance. The per-
centage length of non-viable resected bowel has been shown by
Teitelbaum et al. to be an independent predictor of survival in
patients with postoperative short bowel syndrome (RR ¼ 5.74,
P ¼ .003) [1]. Infants retaining >10% of their expected normal small
intestinal length had an 88.1% survival. Those with <10% had only
21.1% survival. Calculating percentage of expected small bowel
length was essential for statistical signiﬁcance and for being
strongly predictive of survival. On the contrary, actual small bowellength did not carry this predictive value. Furthermore, the study
found that other factors such as number of septic episodes, pres-
ence of the ileocecal valve were not predictive of survival. Inter-
estingly, the etiology of SBS was also non-predictive of mortality.
Thus, our case report is relevant not only to the management of
malrotation but also other conditions which require extensive
neonatal small bowel resection. Multiple studies describe the cor-
relation between absolute length of remnant small bowel and
survival/quality of life in both adult and pediatric short bowel
syndrome [6e8].
Intestinal ischemia, caused by volvulus and obstructing adhesions,
is complicated by a self-perpetuating feed-forward loop of vasocon-
striction. The underlying pathophysiology of non-occlusive mesen-
teric ischemia (NOMI) is currently well deﬁned. The sympathetic
nervous system, humoral factors (such as angiotensin II and vaso-
pressin), and local factors (including prostaglandin and leukotrienes)
regulate blood ﬂow to the intestine [9]. When blood ﬂow to the
intestine is signiﬁcantly compromised, the decrease in pressure
in distal arterial bed triggers the increase in ﬂow of the collateral
vessels [10]. However, after several hours the distal arteries vaso-
constrict and increase the local blood pressure, which induces a
decrease in collateral ﬂow and leads to hypoxia and ischemia.
NOMI results from vasoconstriction that initially serves as a
protective mechanism in the setting of an event which compro-
mises blood ﬂow to the intestines, such as acute myocardial
infarction with shock, arrhythmias, congestive heart failure, and
hypovolemia associated with burns, pancreatitis, hemorrhage and
sepsis [10].
An approach to disrupt this vasoconstrictive feed-forward loop
is the use of vasodilators, such as Papaverine. Papaverine is a non-
xanthine phosphodiesterase inhibitor that is indicated for treat-
ment of vasospasm. The mechanism of action of papaverine’s direct
relaxing properties on smooth muscle are unrelated to innervation
and are due to increases in intracellular cAMP content by inhibiting
phosphodiesterase, thereby increasing cAMP and decreasing the
intracellular calcium concentration that has been released from
storage sites as a results of the provoking insult of vasospasm
[11e13].
Papaverine has been reported to counteract vasospasm in awide
range of clinical settings. It has been used to prevent coronary
reperfusion injury secondary to coronary artery vasospasm [14].
Intrathecal infusion of papaverine has been used to prevent sec-
ondary injury to the injured spinal cord [15]. Papaverine has also
been safely used in neonates to decrease catheter failure rate with
continuous infusion to prolong patency of peripheral arterial
catheters in neonates [16]. Papaverine infused via intra-arterial
pressure catheter has been shown to be useful in the management
of vasospasm in non-occlusive mesenteric ischemia after open
heart surgery [17]. Topical papaverine is used to prevent internal
auditory artery spasm in an animal study [18].
In our case, we demonstrated that use of topical papaverine may
have reduced the percentage of resected potentially non-viable
small bowel. In a review of eight published reports, Weaver et al.
described lengths of small intestine relative to the heights of the
subject [19]. Using their graph, we estimate our patient with a
height of 56 cm to have a small intestine length of 398 cm  4%.
After topical papaverine application, the length of viable small
bowel increased from 62 cm (15.6%) to 92 cm (23.1%). This may be
the ﬁrst reported case of topical papaverine used in a neonate with
ischemic bowels.
3. Conclusion
In our patient, topical intraperitoneal application of papaverine
potentially allowed for the reduction of length of small bowel
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of extensive small bowel resection. This case report warrants
planning of in vivo ischemic murine model testing of intraperito-
neal papaverine. A prospective randomized control study should be
considered to investigate potential beneﬁts of topical papaverine
administration in the setting of the need for massive small bowel
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